2003 Patients Pharmacology 
European Pharmaceutical Review
MARCH 11, 2024
3 While gone are the days when an HIV diagnosis necessitated taking so many pills that patients had to set multiple alarm clocks, self-stigma and concerns of external stigma still exist. With therapeutic expertise in HIV, hepatology and rare diseases, Sherene has additional expertise in clinical pharmacology and drug safety.
European Pharmaceutical Review
SEPTEMBER 22, 2023
Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5
Expert insights. Personalized for you.
98 
Let's personalize your content